Terms of the deal were not disclosed. The deal was first announced in February. The acquired business operates under critical and chronic care solutions division of 3M.

Based in San Diego of California, Ivera develops and markets Curos line of products, including passive disinfection port protectors that disinfect and cover needleless valves to prevent contamination between venous accesses.

According to 3M, the acquired business will allow the firm to expand its vascular access product offerings, helping health care facilities to be provided with cost-effective solutions in the area of hospital acquired infections (HAIs) such as catheter-related blood stream infections or CRBSIs.

Ivera’s product portfolio comprises I.V. port connector caps sold under the Curos Brand, which are used to disinfect and act as a barrier to contamination on devices that provide access to I.V. lines.

The products are said to complement 3M’s vascular access products including Tegaderm CHG (Chlorhexidine Gluconate) I.V. Securement Dressings, which offer critical elements of antimicrobial protection and securement for I.V. site care.

In addition, 3M produces products such as medical tapes, skin care products, bandages and wraps, and skin closures to prevent and treat critical and chronic conditions.